Welcome to our dedicated page for Compass Therapeutics SEC filings (Ticker: CMPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Compass Therapeutics, Inc. (Nasdaq: CMPX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage, oncology-focused biopharmaceutical issuer. Compass develops proprietary antibody-based therapeutics targeting the interplay between angiogenesis, the immune system, and tumor growth, and its filings offer detailed insight into this development activity, its financial position, and material corporate events.
Through Compass Therapeutics’ periodic reports, such as Forms 10-K and 10-Q, investors can review information on research and development expenses, general and administrative costs, cash and marketable securities, lease obligations, and other balance sheet items. These filings also describe the company’s pipeline of antibody-based product candidates, including tovecimig, CTX-8371, CTX-10726, and CTX-471, and outline the clinical and preclinical programs that support its oncology focus.
Current reports on Form 8-K provide more frequent updates on specific events. Recent 8-K filings have covered quarterly and year-to-date financial results, public equity offerings of common stock and pre-funded warrants, and an underwriting agreement related to a registered public offering. These documents describe the terms of financings, expected net proceeds, and stated uses of capital, such as funding research and clinical development, initial commercial readiness activities, and general corporate purposes.
On Stock Titan, users can view Compass Therapeutics’ SEC filings as they are made available through the EDGAR system and can use AI-powered summaries to interpret complex documents. These tools help explain key sections of lengthy filings, highlight important risk disclosures, and clarify how clinical trial progress, cash runway expectations, and capital-raising transactions are reflected in the company’s regulatory reports. In addition, users can track exhibits referenced in 8-K filings, such as underwriting agreements and forms of pre-funded warrants, to better understand the structure of Compass’s capital markets activities.
Compass Therapeutics is a clinical-stage oncology biotech developing antibody-based therapies focused on angiogenesis and immune-oncology pathways. Its lead candidate, tovecimig (DLL4 x VEGF-A), met the study's primary endpoint with a 17.1% overall response rate versus 5.3% for paclitaxel alone (p=0.031), and independent Data Monitoring Committee reviews recommended continuation. The company reports fewer overall survival events than modeled, with pooled OS analyses now expected in Q1 2026.
Financially, Compass recorded a net loss of $19.9 million for the quarter and $36.5 million for the six months, with an accumulated deficit of $401.2 million. Cash, cash equivalents and marketable securities totaled $101 million, which management expects will fund operations into 2027. Research and development expenses rose substantially, driven by increased manufacturing costs for tovecimig and CTX-10726, and the company reported accrued manufacturing obligations including $3.6 million minimum contractual commitments.
Compass Therapeutics furnished a Current Report on Form 8-K announcing that it issued a press release with financial results for the quarter and six months ended June 30, 2025. The press release is included as Exhibit 99.1. The company also furnished the slides presented on its second quarter earnings call as Exhibit 99.2 and its August 2025 corporate presentation as Exhibit 99.3. The filing states that the materials in Item 7.01 (including Exhibit 99.2) are being furnished and not filed, and thus are not subject to Section 18 liabilities or automatically incorporated by reference in other filings. The report discloses the company's common stock trades under the symbol CMPX on the NASDAQ Capital Market. No financial figures are included within the 8-K itself; detailed results are provided in the furnished press release.